GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2012

Cobra Spinout Prokarium Acquires Emergent IP to Boost Oral Vaccine Initiative

  • The Cobra Biologics spinout Prokarium acquired Emergent BioSolutions’ live Salmonella-based typhoid vaccine Typhella™, and oral delivery platform spi-VEC™. Emergent has previously carried out Phase I and II clinical studies demonstrating that Typhella is safe and immunogenic as a typhoid vaccine.

    Prokarium has combined the Typhella and spi-VEC technologies with its own ORT-VAC™ (Operator-Repressor Titration for Vaccines) plasmid stabilization technology to generate a salmonella-based Vaxonella™ platform for the oral delivery of recombinant protein vaccines.

    The Vaxonella platform is being commercialized through licensing agreements, and Prokarium is focusing its own in-house research on the development of a dual oral vaccine candidate Typhetec™ against typhoid and ETEC (enterotoxigenic E.coli). Clinical trials with Typhetec are projected to start during 2013.

    Prokarium’s ORT-VAC™ technology (Operator-Repressor Titration for Vaccines) is the only selectable marker-free plasmid stabilization technology that can function with any type of plasmid, enabling recombinant antigens to be delivered orally.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?